Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Co Ltd exhibits a highly leveraged capital structure, with a debt-to-equity ratio of -1.24, indicating that the company's liabilities significantly exceed its equity. The company's liquidity position is weak, as evidenced by a current ratio of 0.07, suggesting that it may struggle to meet short-term obligations. The negative net cash position, after subtracting total debt, further underscores the company's liquidity challenges. Profitability metrics reveal a concerning trend, with a return on assets (ROA) of -1.0208, indicating that the company is generating losses relative to its asset base. The return on equity (ROE) of 1.5788 is also negative, reflecting the company's inability to generate returns for its shareholders. These figures are likely below the industry median for pharmaceutical companies, which typically maintain positive ROA and ROE due to the high-margin nature of the sector. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in its primary operating region. The company's growth trajectory is negative, with a significant decline in operating income and net income reported in the latest financial period. Analysts have not provided specific growth projections for the next fiscal year, but the current financial performance suggests a challenging outlook. The company faces several risk factors, including liquidity constraints and a high debt burden, which could lead to financial distress if not addressed. The risk assessment indicates a medium liquidity risk and a low dilution risk, suggesting that while the company may struggle with short-term obligations, it is not currently at high risk of issuing additional shares to raise capital. Recent events, including the latest financial filing, highlight the company's deteriorating financial condition, with significant losses and negative cash flows reported. These developments may impact investor confidence and the company's ability to secure financing in the near term.